Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862211 | 0.92 | MEN1 (0.65) | L3MBTL1DRD4ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2627249 | 0.85 | MAPT (0.69) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL4225444 | 0.85 | KDM4E (0.61) | ALDH1A1MAPK1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL1126947 | 0.85 | POLB (0.75) | L3MBTL1DRD4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3151686 | 0.85 | POLB (0.71) | L3MBTL1DRD4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL31349281 | 0.83 | ALDH1A1 (0.74) | DRD4ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL15800712 | 0.82 | ALDH1A1 (0.78) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL11552268 | 0.82 | POLB (0.57) | DRD2ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL6864351 | 0.82 | KDM4E (0.60) | L3MBTL1ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL1126076 | 0.82 | MAPT (0.60) | L3MBTL1ALDH1A1KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000452-B1 | Quinolone-based compounds, formulations, and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000452-B1 | Quinolone-based compounds, formulations, and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-06-19 | — | — | US | disclosed |
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6743796-B2 | PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA; PARKINSON'S DISEASE | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| US-20030013722-A1 | Psychological disorders; schizophrenia; Parkinson's disease | WYETH | 2003-01-16 | — | — | US | disclosed |
| WO-2002090327-A1 | PIPERAZINYL-ISATINS | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | L3MBTL1 2748/4885DRD2 944/4885DRD4 556/4885 |
| US-10000452-B1 | Quinolone-based compounds, formulations, and uses thereof | RECQL, NQO1, NQO2 | L3MBTL1 2343/4885DRD2 4547/4885DRD4 4106/4885 |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | L3MBTL1 2878/4885DRD2 1816/4885DRD4 2795/4885 |
| US-20030013722-A1 | Psychological disorders; schizophrenia; Parkinson's disease | HTR2C, HTR3C, HTR5A | L3MBTL1 3643/4885DRD2 6/4885DRD4 16/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | L3MBTL1 3108/4885DRD2 1504/4885DRD4 2459/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | L3MBTL1 2358/4885DRD2 959/4885DRD4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.